TG Therapeutics, Inc.’s (TGTX) share price has entered into oversold territory with an RSI value of 26.3. The Zacks Consensus Estimate on TG Therapeutics, Inc.’s earnings for the full year period has profit of 0.14 cents over the past two months to $-0.81 per share. Currently, TG Therapeutics, Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (TGTX) after its recent drop.
TG THERAPEUTICS INC (TGTX): Free Stock Analysis Report
Zacks Investment Research